Recently, Cidara Therapeutics Inc. secured European Commission (EC) approval for its lead anti-fungal candidate Rezafungin to treat invasive candidiasis infections in adults, noted H.C. Wainwright & Co.
Salt Lake City-based Clene Inc. reported both encouraging clinical data and a regulatory setback for its ALS drug candidate CNM-Au8, reported Roth MKM.
TRACON Pharmaceuticals Inc. provided an update on enrollment progress for their ongoing Phase 2 ENVASARC clinical trial testing the drug envafolimab to treat sarcoma, reported H.C. Wainwright & Co.
Nkarta is using CRISPR technology for cell therapies for leukemia. The FDA just approved a similar cell therapy treatment for Vertex using the same CRISPR technology. Nkarta is trading well below cash value and has a significant short position sinking underwater.
Recently, Texas-based biotech Bio-Path Holdings Inc. announced it had completed the first safety cohort of a Phase 1/1b trial evaluating the developmental drug BP1002 in acute myeloid leukemia (AML). Read on to see what one Roth analyst has to say about the company's stock.
Humacyte Inc. announced the submission of a Biologics License Application (BLA) to the FDA seeking approval for its lead product candidate Human Acellular Vessel (HAV), noted H.C. Wainwright & Co. Analyst Vernon Bernardino.
This was shown in recent clinical trial results of a biotech's single-dose vaccine against chikungunya evaluated in adults, noted an H.C. Wainwright & Co. report.
These positive results bode well for the biopharma's two polyamine inhibitors as potential treatments for multiple myeloma, noted a ROTH Capital Markets report.
In recent news, Massachusetts clinical-stage biotechnology company Replimune Group Inc. revealed its latest clinical trial did not meet the endpoints needed to call it a success. With this, the stock has plummeted.
Recently, Arcus Biosciences Inc. announced a partnership with Exelixis Inc., which may be the key to validating the company, noted WedBush analysts in a December 4 report.
Recently, BriaCell Therapeutics Corp. announced a new exceptional responder in its Phase 2 study evaluating the company's off-the-shelf personalized immunotherapy, noted H.C. Wainwright analyst Emily Bodnar.
Recently, SpringWorks Therapeutics Inc. announced FDA approval of OGSIVEO (nirogacestat) for treating progressing desmoid tumors (DT) in adult patients based on Phase 3 DeFi trial results, noted H.C. Wainwright & Co. analysts Robert Burns and Dr. Raghuram Selvaraju.
In a recent corporate update, Purple Biotech Ltd. reported positive interim Phase 1/2 data for NT219 and accelerated enrollment for CM24, noted H.C. Wainwright analyst Emily Bodnar.
Oren Livnat of H.C. Wainwright & Co. sees over 240% upside potential for Verrica Pharmaceuticals based on the early commercial success of its recently launched skin disease treatment.
Roth MKM has a US$30 price target on this biotech company based on progress across its regenerative medicine pipeline, including upcoming Phase 1/2 data.
Wedbush sees over 300% upside for Werewolf stock based on early clinical success for its PREDATOR platform and pipeline, according to a WedBush research note.
Cambridge, Massachusetts-based iTeos Therapeutics presented multiple upcoming catalysts into 2024 after reporting Q3 results, noted Wedbush analyst Dr. David Nierengarten.
This Texas-based biotech company's enrollment in its two pivotal Phase 3 trials evaluating lead drug candidate simufilam for Alzheimer's disease surpassed initial enrollment targets, noted H.C. Wainwright analyst Vernon Bernardino.
Chris Temple of The National Investors shares a detailed report on stocks from the life science to the energy sector to tell you which he believes are Buys and which you should sell.
This is one of the California-based company's many transactions resulting from its royalty monetization strategy, noted an H.C. Wainwright & Co. report.
Data will be reviewed from Part B, the dose expansion portion, of the Phase 1 study of a new TGF-β1 isoform inhibitor in advanced cancer, noted a Wedbush report.
First clinical data of this investigational interleukin-2 cytokine show it lacks the degree and rates of adverse events typically seen with treatments of this kind, noted an H.C. Wainwright & Co. report.